Search Results

Gritstone bio, Inc. announced that the Compensation Committee of the company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 6,850 shares of its common stock with an exercise price of $0.75, which is equal to the closing price of Gritstone’s common stock on June 7, 2024, the date of the grant.

Gritstone bio, Inc. today announced the appointment of Stephen Webster to its Board of Directors.

Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced that management will be participating in the following investor and scientific conferences.

Gritstone bio, Inc. today announced that management will be participating in the following investor and scientific conferences.

Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, reported financial results for the first quarter ended March 31, 2024 and provided recent corporate and clinical updates.

Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced an approximately 40% reduction of its workforce.

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today presented an update on its T cell epitope discovery platform, EDGE, at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.

Gritstone bio, Inc. today announced that management will be participating in the following investor and scientific conferences.

Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, presented updated Phase 1 data from its CORAL-CEPI study, a Coalition for Epidemic Preparedness Innovations -funded study that is evaluating Gritstone’s self-amplifying mRNA vaccine against COVID-19 in HIV-negative and people living with HIV participants.

The biotech’s personalized neoantigen vaccine for colorectal cancer did not demonstrate a molecular response difference from the control arm. Gritstone blames trial protocol and plans for a Phase III study.